Log in
E-mail
Password
Show password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON
  1. Homepage
  2. Equities
  3. China
  4. Shenzhen Stock Exchange
  5. Shenzhen Salubris Pharmaceuticals Co., Ltd.
  6. News
  7. Summary
    002294   CNE100000FW8

SHENZHEN SALUBRIS PHARMACEUTICALS CO., LTD.

(002294)
  Report
SummaryChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsOther languagesPress ReleasesOfficial PublicationsSector news

Shenzhen Salubris Pharmaceuticals Co., Ltd. announced that it has received CNY 1.951871178 billion in funding from a group of investors

06/22/2021 EDT

On June 22, 2021, Shenzhen Salubris Pharmaceuticals Co., Ltd. (SZSE:002294) closed the transaction. The company has issued 68,800,535 shares at a price of CNY 28.37 per share for the gross proceeds of CNY 1,951,871,177.95. The transaction included participation from China Southern Fund Management Co., Ltd. for 8,988,365 shares for the gross proceeds of CNY 254,999,915.05, Jinan Jiangshan Investment Partnership (Limited Partnership) for 7,049,700 shares for the gross proceeds of CNY 199,999,989, Caitong Fund Management Co., Ltd. for 5,837,142 shares for the gross proceeds of CNY 165,599,718.54, Li Jianfeng for 4,582,305 shares for the gross proceeds of CNY 129,999,992.85, Ruiyuan Fund Management Co., Ltd. for 4,582,305 shares for the gross proceeds of CNY 129,999,992.85, China Merchants Securities Co., Ltd. for 4,582,305 shares for the gross proceeds of CNY 129,999,992.85, Luo Huanxiao for 4,229,820 shares for the gross proceeds of CNY 119,999,993.4, Wang Guohua for 4229820 shares for the gross proceeds of CNY 119,999,993.4, Guotai Junan Securities Co., Ltd. for 4,088,826 shares for the gross proceeds of CNY 115,999,993.62, Shanghai Shangguo Investment Property Management Co., Ltd. for 3,524,850 shares for the gross proceeds of CNY 9,999,9994.5, Beijing Times Fuxing Investment Management Co., Ltd.-Times Fuxing Panshi No. 6 Private Equity Securities Investment Fund for 3,172,365 shares for the gross proceeds of CNY 89,999,995.05, Du Qunfei for 2,467,395 shares for the gross proceeds of CNY 69,999,996.15, China Securities Co., Ltd. for 2,185,407 shares for the gross proceeds of CNY 61,999,996.59, Shenzhen Tairun Haiji Asset Management Co., Ltd.-Tairun Yuxin Venture Capital No. 6 Private Equity Securities Investment Fund for 2150158 shares for the gross proceeds of CNY 60999982.46, Nordisk Fund Management Co., Ltd. for 2114907 shares for the gross proceeds of CNY 59999911.59, E Fund Management Co., Ltd. for 2114910 shares for the gross proceeds of CNY 59999996.7, Zheng Lei for 2114910 shares for the gross proceeds of CNY 59999996.7, UBS AG for 785045 shares for the gross proceeds of CNY 22271726.65,


ę S&P Capital IQ 2021
Stocks mentioned in the article
ChangeLast1st jan.
SHENZHEN SALUBRIS PHARMACEUTICALS CO., LTD. 1.34% 27.95 End-of-day quote.-1.34%
UBS GROUP AG 0.60% 15.875 Delayed Quote.27.31%
All news about SHENZHEN SALUBRIS PHARMACEUTICALS CO., LTD.
10/07Tranche Update on Shenzhen Salubris Pharmaceuticals Co., Ltd.'s Equity Buyback Plan ann..
CI
09/05Shenzhen Salubris Pharmaceuticals Co., Ltd. announces an Increase in Equity Buyback.
CI
08/23Viracta Up 5% After It Reacquires Rights to Combination Therapy in China
DJ
08/23VIRACTA THERAPEUTICS : Reacquires Exclusive Rights to Combination Therapy Candidate for Ly..
MT
08/23Shenzhen Salubris Pharmaceuticals Co., Ltd. Reports Earnings Results for the Half Year ..
CI
08/06SKILLFUL CRAFTSMAN EDUCATION TECHNOL : Names Dawei Chen as Chief Financial Officer
MT
07/25Shenzhen Salubris Pharmaceuticals Co., Ltd. announces an Equity Buyback for CNY 200 mil..
CI
07/25Shenzhen Salubris Pharmaceuticals Co., Ltd. authorizes a Buyback Plan.
CI
07/25SHENZHEN SALUBRIS PHARMACEUTICALS CO : 002294) intends to launch an Equity Buyback Plan.
CI
07/02Salubris Biotechnology Co., Ltd. announced that it expects to receive CNY 263.8 million..
CI
More news
Financials
Sales 2021 2 801 M 435 M 435 M
Net income 2021 684 M 106 M 106 M
Net cash 2021 627 M 97,5 M 97,5 M
P/E ratio 2021 42,7x
Yield 2021 0,95%
Capitalization 31 159 M 4 842 M 4 843 M
EV / Sales 2021 10,9x
EV / Sales 2022 9,08x
Nbr of Employees 3 448
Free-Float 35,3%
Chart SHENZHEN SALUBRIS PHARMACEUTICALS CO., LTD.
Duration : Period :
Shenzhen Salubris Pharmaceuticals Co., Ltd. Technical Analysis Chart | 002294 | CNE100000FW8 | MarketScreener
Technical analysis trends SHENZHEN SALUBRIS PHARMACEUTICALS CO., LTD.
Short TermMid-TermLong Term
TrendsBullishBearishNeutral
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus HOLD
Number of Analysts 3
Last Close Price 27,95 CNY
Average target price 26,50 CNY
Spread / Average Target -5,19%
EPS Revisions
Managers and Directors
Sing Ye General Manager & Director
Jun Liu Chief Financial Officer
Cheng Hai Ye Chairman
Ai Zhen Li Chairman-Supervisory Board
Ji Tang Member-Supervisory Board & Administrative Director